E-ISSN: 1308-5255 ISSN: 1307-7635
Cetuximab Induced Acneiform Eruption, Telangiectasia, Hypertrichosis, Paronychia, and Digital Fissures: a Case Report
PDF
Cite
Share
Request
Case Report
VOLUME: 13 ISSUE: 1
P: 42-45
March 2019

Cetuximab Induced Acneiform Eruption, Telangiectasia, Hypertrichosis, Paronychia, and Digital Fissures: a Case Report

Turk J Dermatol 2019;13(1):42-45
DOI: 10.4274/tdd.galenos.2014.2315
Mehmet Ünal 1
Gülbahar Ürün Ünal 2
Şevket Arslan 3
Hüseyin Tol 4
Şükrü Balevi 4
1. Konya Numune Hastanesi, Deri ve Zührevi Hastalıkları Kliniği, Konya, Türkiye
2. Konya Eğitim ve Araştırma Hastanesi, Aile Hekimliği Kliniği, Konya, Türkiye
3. Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi, Göğüs Hastalıkları Kliniği, Konya, Türkiye
4. Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi, Deri ve Zührevi Hastalıklar Kliniği, Konya, Türkiye
No information available.
No information available
Received Date: 23.05.2014
Accepted Date: 10.11.2014
Publish Date: 22.03.2019
PDF
Cite
Share
Request

ABSTRACT

Epidermal growth factor plays a critical role in tumor growth and progression, including cell proliferation, inhibition of apoptosis, angiogenesis, invasion, and metastasis. Cetuximab is the first monoclonal antibody that effects by binding to epidermal growth factors in the treatment of metastatic colorectal cancer. Because of the increasingly frequent use of epidermal growth factors inhibitors such as cetuximab in oncology services, perhaps more patients with the dermatologic complaints may require evaluation by dermatologists. Here, we report a case of severe acneiform eruption, hypertrichosis, telangiectasia, paronychia, ingrown toenails, pyogenic granuloma-like lesions, and digital fissures due to cetuximab in a 53-year-old female patient with colorectal cancer with metastases.

References

1
Kılıç A. Epidermal büyüme faktör reseptör inhibitörleri ve dermatolojik yan etkiler. Turk J Dermatol 2012;6:168-74.
2
Arıcan Ö, Önver N. Setuksimab Tedavisine Bağlı Akneiform Erüpsiyon: Bir Olgu Sunumu. Turk J Dermatol 2011;5:29-32.
3
Sinclair R. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors. Asia Pac J Clin Oncol 2014;10 Suppl 1:11-7.
4
Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011;16:228-38.
5
Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56:317-26.
6
Galimont-Collen AF, Vos LE, Lavrijsen AP, et al. Classification and management of skin, hair, nail and mucosal side- effects of epidermal growth factor receptor(EGFR) inhibitors. Eur J Cancer 2007;43:845-51.
7
Yalçin S, Dizdar O, Yalçin B, et al. Sparing of previously irradiated skin from erlotinib-induced acneiform rash. J Am Acad Dermatol 2008;58:178-9.
8
Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol 2010;24:453-9.
9
Tomková H, Kohoutek M, Zábojníková M, et al. Cetuximab-induced cutaneous toxicity. J Eur Acad Dermatol Venereol 2010;24:692-6.